DrugPatentWatch Database Preview

Details for Patent: 9,192,608

« Back to Dashboard

Which drugs does patent 9,192,608 protect, and when does it expire?

Patent 9,192,608 protects MORPHINE SULFATE and is included in one NDA.

This patent has eight patent family members in six countries.

Summary for Patent: 9,192,608

Title:	Morphine formulations
Abstract:	Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
Inventor(s):	Cuine; Alain (St. Fargeau-Ponthierry, FR), Hoarau; Didier (Claix, FR), Romain; Pauline (Saint Egreve, FR)
Assignee:	BECTON DICKINSON FRANCE S.A.S. (Le Pont de Claix, FR)
Application Number:	14/715,277
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,192,608

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Fresenius Kabi Usa	MORPHINE SULFATE	morphine sulfate	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	204223-001	Oct 30, 2013		RX	Yes	Yes						TREATMENT OF PAIN
Fresenius Kabi Usa	MORPHINE SULFATE	morphine sulfate	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	204223-001	Oct 30, 2013		RX	Yes	Yes						MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
Fresenius Kabi Usa	MORPHINE SULFATE	morphine sulfate	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	204223-002	Oct 30, 2013		RX	Yes	Yes						MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
Fresenius Kabi Usa	MORPHINE SULFATE	morphine sulfate	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	204223-002	Oct 30, 2013		RX	Yes	Yes						TREATMENT OF PAIN
Fresenius Kabi Usa	MORPHINE SULFATE	morphine sulfate	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	204223-003	Oct 30, 2013		RX	Yes	Yes						TREATMENT OF PAIN

Non-Orange Book US Patents Family Members for Patent 9,192,608

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,072,781	Morphine formulations

International Family Members for US Patent 9,192,608

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2902343
China	104042565
European Patent Office	2968132
European Patent Office	3143988
Japan	2016512210